Michael John Clare

This inventor holds 87 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 6 EPO patents, primarily in Pharmaceutical Innovations (CPC class C07D401-12). Top assignees: G.d. Searle & Company, Pharmacia Corporation, Imago Biosciences, Inc.. Active years: 1988-2025.

USPTO Granted Patents = 87 (Patent Applications = 3)

% Patents Active = 71.3

CIPO Patents = 3 (Patent Applications = 9)

EPO Patents = 6 (Patent Applications = 5)

Average Co-Inventor Count = 5.8

ph-index = 15

Forward Citations = 724(Granted Patents)

Forward Citations (Not Self Cited) = 636(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Stokie, IL (US) (1989)
Sokie, IL (US) (1998)
Skokie, IL (US) (1988 - 2024)
Sylva, NC (US) (2021 - 2024)

Company Filing History:

36 out of 1,323

G.d. Searle & Company

patents

13 out of 220

Pharmacia Corporation

patents

10 out of 11

Imago Biosciences, Inc.

Beryllium Discovery Corp.

Northern Illinois University

Anovia Biosciences, Inc.

patent

11. 1 out of 2

Monsanto Company of St. Louis

Pharmacia Corporation (Monsanto Corporation)

patent

14. 4 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 1988-2025

Loading Chart...

Areas of Expertise:

KDM1A Inhibitors

Retroviral Protease Inhibitors

Inflammation Treatments

Heterocyclic Compounds

Oxalate-Related Diseases

Automated Pill Dispenser

Integrin Receptor Antagonists

Isoprenoid Biosynthesis

PASK Inhibition

Pyrazole Compounds

Cyclic Sulfone

Substituted Indoles

87 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12213976 - Compounds and methods for treating oxalate-related diseases (2025-02-04),

2. 12053575 - Devices and methods for delivering fluid to a nasal cavity (2024-08-06),

3. 12016864 - LOX enzyme inhibiting methods and compositions (2024-06-25),

4. 11932629 - KDM1A inhibitors for the treatment of disease (2024-03-19),

5. 11773068 - KDM1A inhibitors for the treatment of disease (2023-10-03),

6. 11655226 - KDM1A inhibitors for the treatment of disease (2023-05-23),

7. 11610657 - Automated pill dispenser (2023-03-21),

8. 11578059 - KDM1A inhibitors for the treatment of disease (2023-02-14),

9. 11504367 - Compounds and methods for treating oxalate-related diseases (2022-11-22),

10. 11459307 - Heterocyclic compounds for the inhibition of PASK (2022-10-04),

11. 11230534 - KDM1A inhibitors for the treatment of disease (2022-01-25),

12. 11052205 - Devices and methods for delivering fluid to a nasal cavity (2021-07-06),

13. 10882835 - KDM1A inhibitors for the treatment of disease (2021-01-05),

14. 10781185 - Heterocyclic compounds for the inhibition of PASK (2020-09-22),

15. 10519118 - KDM1A inhibitors for the treatment of disease (2019-12-31),

Title: The Visionary Innovations of Michael John Clare

Introduction: Michael John Clare, a visionary inventor based in Sylva, NC (US), is a trailblazer in the field of technology with a remarkable career spanning several decades. His passion for innovation and relentless pursuit of excellence have solidified his reputation as a pioneer in the world of inventions.

Latest Patents: With an impressive portfolio of 84 patents, Michael John Clare continues to revolutionize the industry with his latest groundbreaking inventions. One of his recent patents includes the development of KDM1A inhibitors for the treatment of various diseases such as acute myelogenous leukemia. These compounds and methods offer promising solutions for the prevention and treatment of life-threatening conditions.

Career Highlights: Michael John Clare has made significant contributions to renowned companies such as G.D. Searle & Company and Pharmacia Corporation. His innovative mindset and dedication to pushing boundaries have led to the successful development of numerous groundbreaking technologies that have reshaped the landscape of the industry.

Collaborations: Throughout his illustrious career, Michael John Clare has collaborated with esteemed professionals in the field, including his coworkers Michael L Vazquez and Daniel P Getman. These collaborations have fueled creativity, fostered new ideas, and ultimately resulted in the creation of cutting-edge inventions that have left a lasting impact on the world of technology.

Conclusion: In conclusion, Michael John Clare's unwavering dedication to innovation, coupled with his relentless pursuit of excellence, has established him as a true visionary inventor. His contributions continue to inspire the next generation of inventors and shape the future of technology, leaving a lasting legacy in the world of inventions.